Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

FTV · Q3 2025 Earnings

Fortive

Reported October 29, 2025

30-second summary

Fortive printed $1.027B revenue (+2.3% YoY, core +1.9%) and $0.68 non-GAAP EPS (+15.3% YoY), and raised the FY25 EPS guide to $2.63–$2.67 from $2.50–$2.60 — a $0.10 midpoint lift (+3.9%) that resolves last quarter's "walkdown to the low end" risk in the opposite direction. The catch: management explicitly guided Q4 core growth to moderate from Q3's 1.9%, with IOS framed as "very modest" — so the EPS raise is being funded by margin expansion (adjusted EBITDA margin 30.1%, IOS at 34.6%) and deliberate reinvestment, not by a top-line inflection.

Headline numbers

EPS

Q3 FY2025

$0.68

Revenue

Q3 FY2025

$1.03B

+2.3% YoY

Gross margin

Q3 FY2025

63.2%

Free cash flow

Q3 FY2025

$0.27B

Operating margin

Q3 FY2025

15.5%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$1.03B	+2.3%	$1.02B	+1.1%
EPS	$0.68	—	$0.58	+17.2%
Gross margin	63.2%	—	63.5%	-30bps
Operating margin	15.5%	—	16.7%	-120bps
Free cash flow	$0.27B	—	$0.18B	+47.8%

Guidance

Fortive raised full-year 2025 EPS guidance by $0.03–$0.07 (to $2.63–$2.67) on strong Q3 adjusted EPS performance, while signaling Q4 core growth moderation and introducing new tax-rate guidance.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

Metric	Period	Guide	YoY
Adjusted Effective Tax Rate	FY2025	mid-teens	—
Core Revenue Growth	Q4 FY2025	modest (overall); AHS broadly in line with Q3 (~1.9%); IOS very modest	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted Diluted EPS	FY2025	$2.50 to $2.60	$2.63 to $2.67	+$0.03 to +$0.07 at both ends	Raised

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Intelligent Operating Solutions	$0.699B	+2.6%
Advanced Healthcare Solutions	$0.328B	+1.9%
IOS Adjusted EBITDA Margin	34.6%	—
AHS Adjusted EBITDA Margin	28.1%	—

Other KPIs

Q3 FY2025

Segment	Q3 FY2025
Adjusted EBITDA Margin	30.1%
Core Revenue Growth	1.9%
Adjusted EBITDA	$309M
Adjusted Diluted EPS YoY Growth	15.3%

Management tone

Q1 anchor: "Tariff offset plan with structured timeline" → Q2 anchor: "Deferred spending narrative with reduced visibility" → Q3 anchor: "Offensive growth pivot funded by margin reinvestment"

The CEO has reframed FBS from operational lean tool to growth engine — a deliberate reversal of Fortive's three-decade identity. Q1 and Q2 commentary leaned on FBS as a cost-control and tariff-offset mechanism; this quarter management asserted: "Our Fortive business system is powerful, not just for leadership and lean, but as a systematic growth engine." The repositioning is paired with creating "growth oxygen" for the ten operating brands and an overhauled strategic planning process. This is the most offensive posture Fortive has taken in years and explicitly contradicts the measured, steady-state narrative that defined the pre-spin company.

Margin expansion is now being explicitly converted into reinvestment, not flow-through. Q2's framing positioned margins as constrained by tariff and deferral headwinds; this quarter management said: "we've also created space in our P&L, as you saw with the big margin expansion in Q3, so we can actually put some more investment behind this growth idea... we do expect to redeploy some of the resources we freed up in the fourth quarter." That sentence reframes the Q4 setup — the EPS raise is what's left after deliberate reinvestment, and Q4 operating leverage may be deliberately muted to fund 2026 acceleration. It also partly explains why core growth is being guided down even as confidence is up.

Healthcare narrative inverted from "policy headwind" to "supply-constrained demand." Q1 and Q2 framed AHS softness as reimbursement and funding policy uncertainty pressuring procurement; this quarter management said "we certainly see improvement in the demand patterns... significantly in September especially... we began to see more and more of those get funded in September," positioning the recovery as customer-funding-driven with structural demographic tailwinds intact. AHS's revenue inflection supports the reframing but the Q4 guide of "in line with Q3" caps the optimism.

M&A philosophy hardened from "bolt-ons with elevated scrutiny" to "explicitly not required." Q2 noted tighter M&A standards; this quarter the CEO said: "the formula we laid out for shareholder value creation the next three years does not require us to do M&A." Combined with the explicit prioritization of buybacks at attractive valuations, this signals the spinoff-era discipline is hardening into a multi-year capital allocation framework — buybacks and small bolt-ons, no transformational deals.

Recurring themes management leaned on this quarter:

Simplification enabling customer-centric accelerationRecurring revenue trajectory (already 15% at Fluke, targeting higher mix)North America momentum vs. Western Europe softnessDisciplined capital allocation prioritizing buybacks at attractive valuationsFBS system evolved from operational excellence to growth engineHealthcare resilience despite 2025 policy choppiness with underlying demographic tailwinds

Risks management surfaced:

Global trade policy volatility and tariff uncertainty despite Q3 countermeasuresWestern Europe macro conditions remaining soft with no expected dramatic improvement in Q4Healthcare reimbursement and funding policy changes creating near-term deferral riskPillar 2 tax framework risk if US not excluded could drift tax rate above mid-teensGovernment shutdown impact on state/local agencies (though noted as small direct exposure)

Answers to last quarter's watch list

Q3 phasing commentary vs. the "July is looking better" signal — The deferred-spending thesis was substantively validated. Core growth came in at +1.9%; revenue rose to $1.027B; both segments inflected positive. Management's "demand patterns improving significantly in September" framing suggests the late-Q2 shortfall reversed.

Resolved positively

Gordian sequential recovery — Not directly quantified, but IOS revenue grew +2.6% YoY and IOS adjusted EBITDA margin expanded to 34.6%, consistent with state/local procurement normalizing — though management noted continued pressure on government-facing procurement and estimating solutions from tighter fiscal policy. The Q4 IOS guide of "very modest" core growth tempers the read — the recovery may be partial, not full.

Continue monitoring

AHS operating margin trajectory — AHS adjusted EBITDA margin reached 28.1% (+120bps YoY vs Q3-24's 26.9%), with revenue growth inflecting to +1.9% YoY reported (+1.1% core). Management framed the improvement as sequential demand acceleration in equipment and consumables, not a discrete dislocation.

Resolved positively

Tariff offset execution evidence — Management stated tariffs net of countermeasures are "not expected to be material" in Q4, consistent with the Q1 commitment of full offset by Q4. Adjusted gross margin was down ~60bps YoY due to tariff cost, partly offset by pricing and supply chain countermeasures. The Q4 milestone now appears in reach.

Resolved positively

FY25 EPS range walkdown — The opposite happened: the range was raised to $2.63–$2.67 from $2.50–$2.60, with the new low end above the prior midpoint of $2.55. The cautious Q2 read is overturned.

Resolved positively

What to watch into next quarter

Q4 core growth delivery vs. the "modest / very modest IOS" guide — Management has set a low bar; watch whether IOS comes in flat-to-modestly-positive or actually decelerates. A negative IOS print would validate the "hidden cut" concern.

Q4 EPS landing within $0.82–$0.86 implied range — given the FY guide and Q1–Q3 prints, watch the operating vs. tax-driven mix. If the Q4 single-digit tax rate is the primary lever, the operational raise is narrower than the headline suggests.

Reinvestment ROI evidence at Fluke and recurring revenue mix — management cited Fluke's progress on recurring revenue through maintenance software and service plans; watch any quantification of recurring revenue traction across the IOS portfolio as the FBS-as-growth-engine thesis is tested.

Buyback pace and capital deployment — with management explicitly stating M&A is not required for the three-year value creation framework, watch the Q4 share repurchase tape and any update to authorization. A material buyback acceleration would confirm the capital allocation pivot.

Sources

Fortive Q3 FY2025 press release: https://www.sec.gov/Archives/edgar/data/1659166/000165916625000129/q32025-ex991.htm
Fortive Q3 FY2025 earnings call transcript excerpts (as supplied in extraction inputs).
Fortive Q2 FY2025 Tapebrief brief for cross-quarter tone, guidance, and watch-list comparison.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.